Bayer: 5 new Phase III drugs expected in 2015

Share this article:

Bayer said Tuesday that it is accelerating its pipeline and expects to have five drugs in Phase III testing in 2015. The drug maker said in a statement that the drugs will swell its oncology, cardiology and women's health list of experimental treatments.

This is in addition to working on expanding the list of indications for drugs including heart drug Xarelto, cancer medication Xofigo and eye treatment Eylea.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.